← 返回

核因子 ID3 赋予巨噬细胞强大的抗肿瘤活性

英文原题:The nuclear factor ID3 endows macrophages with a potent anti-tumour activity.

查看英文原题

The nuclear factor ID3 endows macrophages with a potent anti-tumour activity.

PubMed 2024/02/07(内容时间) Nature Q1 · IF 56.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

巨噬细胞活化由活化性和抑制性受体之间的平衡控制1-7,这种平衡在感染期间保护正常组织免受过度损伤8,9,但在癌症中促进肿瘤生长和转移7,10。在此我们报道,Kupffer细胞谱系决定因子ID3控制这一平衡,并选择性地赋予Kupffer细胞吞噬活肿瘤细胞以及协调NK 细胞和CD8 T淋巴效应细胞在肝脏中募集、增殖和活化的能力,从而限制多种肿瘤的生长。ID3改变巨噬细胞抑制性/活化性受体平衡以促进吞噬和淋巴样反应,至少部分是通过缓冲转录因子ELK1和E2A在SIRPA位点上的结合来实现的。此外,功能缺失和功能获得实验表明,ID3足以将这种强效抗肿瘤活性赋予小鼠骨髓来源巨噬细胞和人诱导多能干细胞来源巨噬细胞。因此,ID3的表达对于赋予巨噬细胞形成有效抗肿瘤微环境的能力是必要且充分的,这一能力可用于癌症的细胞治疗。

展开英文摘要原文

Macrophage activation is controlled by a balance between activating and inhibitory receptors 1-7 , which protect normal tissues from excessive damage during infection 8,9 but promote tumour growth and metastasis in cancer 7,10 .

Here we report that the Kupffer cell lineage-determining factor ID3 controls this balance and selectively endows Kupffer cells with the ability to phagocytose live tumour cells and orchestrate the recruitment, proliferation and activation of natural killer and CD8 T lymphoid effector cells in the liver to restrict the growth of a variety of tumours.

ID3 shifts the macrophage inhibitory/activating receptor balance to promote the phagocytic and lymphoid response, at least in part by buffering the binding of the transcription factors ELK1 and E2A at the SIRPA locus.

Furthermore, loss- and gain-of-function experiments demonstrate that ID3 is sufficient to confer this potent anti-tumour activity to mouse bone-marrow-derived macrophages and human induced pluripotent stem-cell-derived macrophages. Expression of ID3 is therefore necessary and sufficient to endow macrophages with the ability to form an efficient anti-tumour niche, which could be harnessed for cell therapy in cancer.

论文信息

作者
Deng Z、Loyher PL、Lazarov T、Li L、Shen Z、Bhinder B、Yang H、Zhong Y
第一作者单位
Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.United States
通讯作者单位
Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. geissmaf@mskcc.org.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Nature2024 Feb
原文标识
PubMed 38326607 · DOI 10.1038/s41586-023-06950-4